Telmisartan is an angiotensin-II type 1 receptor (AT1R) blocker, currently used to treat patients with hypertension. Telmisartan, in addition to its effect on AT1R, is thought to activate the nuclear transcription factor, peroxisome proliferator-activated receptor-c (PPAR c), thereby acting as a partial PPARc agonist. This study was conducted to examine whether telmisartan might suppress cytokine-induced inflammatory signaling in vascular endothelial cells, thereby attenuating cellular inflammation possibly by PPARc activation. Telmisartan caused a dose-dependent suppression of the tumor necrosis factor-a (TNFa)-induced activation of nuclear factor (NF)-jB in vascular endothelial cells in this study. The PPARc antagonist, GW9662, did not influence the inhibitory effect of telmisartan on NF-jB activation. The thiazolidinediones neither influenced TNFa-induced NF-jB activation nor influenced the inhibitory effect of telmisartan in this process. Telmisartan dose dependently diminished the TNFa-induced gene expression of VCAM-1, and GW9662 did not attenuate this effect. Thus, telmisartan inhibits the cytokine-induced expression of the VCAM-1 gene by blocking NF-jB activation independently of PPARc activation. Although the mechanism by which this occurs remains unclear, our findings suggest that telmisartan-induced anti-inflammatory effects might have favorable effects on vasculature in hypertensive patients.
INTRODUCTION
Atherogenesis results from inflammation within the vessel wall. 1 The renin-angiotensin system (RAS) has an important role in vascular hemostasis. Angiotensin II (Ang II), the main effector of the system, is thought to promote vascular inflammation and atherosclerosis. 2 Ang II exerts its effects through the Ang type 1 (AT1R) and type 2 (AT2R) receptors. 3 The AT1R is the predominant receptor of the cardiovascular system and mediates most of the deleterious effects of Ang II, such as vasoconstriction, endothelial damage and cellular proliferation. 3 It has been convincingly shown that inhibition of RAS by an angiotensin-converting enzyme (ACE)-inhibitor or an AT1R antagonist reduces cardiovascular disease. [4] [5] [6] Telmisartan is an AT1R blocker, currently used to treat patients with hypertension. Recent data suggest that telmisartan, in addition to being an AT1R antagonist, can activate the nuclear transcription factor of peroxisome proliferator-activated receptor-g (PPARg), [7] [8] [9] thereby acting as a partial PPARg agonist. PPARg is involved in the regulation of glucose homeostasis, in insulin resistance and lipoprotein metabolism. Thus, activators of PPARg, such as thiazolidinediones (TZDs), rosiglitazone and pioglitazone, are used clinically in the treatment of diabetes. 10 Furthermore, recent data suggest that telmisartan has anti-inflammatory and antioxidant properties. 11, 12 Therefore, this study was conducted to examine the effect of telmisartan on cytokine-induced inflammatory signaling, as well as the relationship between cellular inflammation and PPARg-activation in vascular endothelial cells.
METHODS

Cell culture
Human umbilical vein endothelial cells (HUVECs) were obtained from Clonetics (San Diego, CA, USA) and cultured in an EGM2 medium supplemented with 2% fetal calf serum (FCS) in the standard manner. The cells in this experiment were used within 3-4 passages and were examined to ensure that they demonstrated the specific characteristics of endothelial cells. SVEC4 cells (murine endothelial cell line; ATCC, Rockville, MD, USA) were also cultured in Dulbecco's modified Eagle's medium containing 10% FCS and were observed to show the typical cobblestone morphological appearance of endothelial cells. 13 Nuclear factor-jB activation To study nuclear factor (NF)-kB activation, SVEC4 cells were stably transfected with a cis-reporter plasmid containing the luciferase reporter gene linked to five repeats of the NF-kB-binding site (pNFkB-Luc: Stratagene, La Jolla, CA, USA), as previously described. 14 For this, the pNFkB-Luc plasmid was transfected, together with a pSV2neo helper plasmid (Clontech, Palo Alto, CA, USA), into SVEC4 cells using a FuGEN 6 transfection reagent (Boehringer Mannheim, Mannheim, Germany). The cells were then cultured in the presence of G418 (Clontech) at a concentration of 500 mg ml À1 and the medium was replaced every 2-3 days. Approximately 3 weeks after transfection, G418-resistant clones were isolated using a cloning cylinder and analyzed individually for the expression of luciferase activity. Several clones were also selected for the analysis of NF-kB activation. Luciferase activity was measured using a luciferase assay kit (Stratagene).
We also measured changes in the levels of NF-kB p50 and p65 in nuclear extracts from HUVECs using a transcription factor assay kit (Active Motif Japan, Tokyo, Japan). Nuclear extracts were prepared with an NE-PER nuclear extraction reagent (Pierce, Rockford, IL, USA), after which p50 and p65 were quantified using a Jurkat nuclear extract as the standard.
Western blot analysis
Human umbilical vein endothelial cells treated with telmisartan for various intervals were lyzed using a cell lysis buffer (Cell Signaling, Beverly, MA, USA) with 1 mM phenylmethylsulfonyl fluoride. The protein concentration of each sample was measured using a Bio-Rad detergent-compatible protein assay (BioRad, Tokyo, Japan). Subsequently, b-mercaptoethanol was added to a final concentration of 1%, after which each sample was denatured by boiling for 3 min. Samples containing 10 mg of protein were resolved by electrophoresis on a 12% SDS-polyacrylamide gel and transferred to a polyvinyldienefluoride membrane (Bio-Rad), after which they were incubated with an anti-phosphoThr-172 AMPK polyclonal antibody (1:1000, Cell Signaling). The binding of each of these antibodies was detected using sheep anti-rabbit IgG in horseradish peroxidase (1:20 000) and an ECL Plus system (Amersham, Buckinghamshire, UK).
Real-time PCR of HUVEC mRNA
For the quantitative measurement of mRNA, 2 mg of total RNA was treated with DNase I for 15 min and subsequently used for cDNA synthesis. Reverse transcription was carried out using a SuperScript pre-amplification system (Gibco BRL, Gaithersburg, MD, USA) with random oligonucleotide primers. The following primers were used: VCAM-1 forward 5¢-GGCAGAGTACG CAAACACTT-3¢ and reverse 5¢-GGCTGTAGCTCCCCGTTAG-3¢, as well as GAPDH forward 5¢-GGAGAAGGCTGGGGCTCAT-3¢ and reverse 5¢-TGATGGCATGGACTGTGGTC-3¢. A typical reaction (50 ml) contained 1/50 of reverse transcription (RT)-generated cDNA and 200 nM of primer in a 1Â SYBR Green RealTime Master Mix (Toyobo, Tokyo, Japan) buffer. The PCRs were carried out in a LineGene system (BioFlux, Tokyo, Japan) under the following conditions: 951C for 5 min, followed by 40 cycles at 95 1C for 15 s, 60 1C for 15 s and 721C for 30 s.
Statistical analysis
Data are presented as mean values±s.e.m. Multiple comparisons were evaluated by analysis of variance, followed by Fisher's protected least-significant difference test. A value of Po.05 was considered to be statistically significant.
RESULTS
Telmisartan inhibits NF-jB activation
We initially examined the effects of a 2 h incubation with tumor necrosis factor-a (TNFa) on NF-kB activation in SVEC4 cells. TNFa induced a sevenfold increase in the NF-kB-mediated reporter gene expression. Telmisartan dose dependently suppressed the TNFainduced activation of NF-kB, although it had no effect on basal NF-kB activity (Figure 1a) .
We also used HUVEC to measure p50 and p65 in nuclear extracts from untreated cells and from cells treated with TNFa in the presence or absence of telmisartan. Marked increases in p50 and p65 were observed 30 min after stimulation with TNFa from very low baseline levels. The observed increases in p50 and p65 were significantly attenuated by telmisartan in a dose-dependent manner (Figure 1b) .
Effect of a PPARc agonist and antagonist on NF-jB activation
We next examined the effect of the PPARg antagonist, GW9662, on the telmisartan-induced inhibition of NF-kB. GW9662 (10 À6 M) did not influence the inhibitory effect of telmisartan on the NF-kBmediated reporter gene expression (Figure 2a) .
We also examined the effects of troglitazone, rosiglitazone and pioglitazone on TNFa-induced NF-kB activation in the presence or absence of telmisartan. The TZDs did not affect TNFa-induced NF-kB activation and did not attenuate telmisartan-induced NF-kB activation (Figure 2b) .
Effect of duration of incubation with telmisartan and effect of AMP-activated protein kinase
We examined the effect of varying the duration of incubation with telmisartan before and after exposure to TNFa on NF-kB activity. SVEC4 cells were exposed to telmisartan 180 or 30 min before, at the HUVECs were stimulated with TNFa in the presence or absence of telmisartan (T30: 30 mM, T100: 100 mM) for 30 min. NF-kB p65 or p50 subunits were then quantified within nuclear extracts using a transcription factor assay kit using the Jurkat nuclear extract as the standard. Data represent the means ± s.d. (n¼4). *Po0.05, **Po0.01.
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A Nakano et al same time or 30 min after the addition of TNFa. A longer preincubation with telmisartan caused a more marked suppression of TNFa-induced NF-kB activation. However, telmisartan still showed a significant inhibitory effect when added 30 min after TNFa (Figure 3a) . Treatment of HUVEC with metformin resulted in a time-dependent activation of AMP-activated protein kinase (AMPK), as monitored by the phosphorylation of AMPK (positive control), whereas telmisartan did not activate AMPK. Accordingly, the AMPK inhibitor compound C did not influence the inhibitory effect of telmisartan on TNFainduced NF-kB activation (Figure 3b ).
Telmisartan inhibits induction of VCAM-1 mRNA
Incubation of HUVEC for 16 h with TNFa substantially induced the gene expression of VCAM-1. However, this TNFa-mediated induction of gene expression was markedly suppressed by a co-treatment with the NF-kB inhibitor, BAY11-7082, which selectively and irreversibly inhibits cytokine-induced IkB phosphorylation, 15 suggesting that induction of the VCAM-1 gene is NF-kB dependent (data not shown). Co-incubation with telmisartan dose dependently diminished the TNFa-induced gene expression of VCAM-1, whereas GW9662 (10 À6 M) did not influence the inhibitory effect of telmisartan on VCAM-1 gene expression (Figure 4) . Telmisartan inhibits NF-jB independently of PPARc A Nakano et al PPARg antagonist, GW9662, had no effect on the telmisartanmediated inhibition of TNFa-induced NF-kB activation. The TZDs neither suppressed TNFa-induced NF-kB activation nor influenced the inhibitory effect of telmisartan in this process. This confirms that telmisartan inhibits TNFa-induced NF-kB activation independently of PPARg activation. Thus, PPARg activation probably does not have a large role in the anti-inflammatory effect of telmisartan in endothelial cells, even though TZDs reportedly reduce inflammation in this cell type. 16, 17 Telmisartan has been shown to increase adiponectin levels in humans, perhaps because of an effect on PPARg, which shows a high level of expression in adipocytes to produce adiponectin. 18 On the other hand, PPARg expression might be limited in endothelial cells, thereby explaining the more important role of an alternative antiinflammatory mechanism of telmisartan in this cell type. Angiotensin II by itself induces NF-kB activation, although to a much lesser extent compared with TNFa. Thus, it is possible for telmisartan to cause an inhibitory signaling on the NF-kB activation pathway through AT1R. However, this awaits elucidation. Inhibition of the TNFa-induced activation of NF-kB by telmisartan was directly related to the length of incubation in this study. A longer preincubation with telmisartan caused a more marked suppression of TNFa-induced NF-kB activation. This might suggest that telmisartan induces the production of an anti-inflammatory protein that inhibits NF-kB activation. However, telmisartan still showed a significant inhibitory effect when added 30 min after exposure to TNFa, suggesting another mechanism of action. We have recently shown that AMPK-activating agents such as metformin, 19 cilostazol 20 and fenofibrate 21 inhibit cytokine-induced NF-kB activation. Thus, we examined whether telmisartan might also activate AMPK. Telmisartan was not found to activate AMPK as the AMPK inhibitor compound C had no effect on the telmisartan-mediated inhibition of TNFa-induced NF-kB activation. It has been recently shown that the interaction between NF-kB and TNFa signaling induces the activation of IKKb and amplifies oxidative stress, leading to endothelial dysfunction in type 2 diabetics. Thus, telmisartan might inhibit IKKb; however, it is still to be elucidated. 22 Incubation of HUVEC with TNFa significantly induced VCAM-1 gene expression. The induction of TNFa-induced VCAM-1 mRNA expression is known to be markedly suppressed by co-treatment with the NF-kB inhibitor, BAY11-7082, 15 suggesting that induction of VCAM-1 mRNA is NF-kB dependent. Accordingly, telmisartan inhibited VCAM-1 mRNA induction, which was not affected by the PPARg antagonist, GW9662.
In conclusion, this study demonstrated that telmisartan inhibits cytokine-induced adhesion molecule gene expression by blocking NF-kB activation independently of PPARg activation in vascular endothelial cells. The mechanism by which this occurs remains unclear. Although experiments on cultured cells do not necessarily reflect what occurs in vivo, our findings suggest that telmisartan may have an anti-inflammatory effect on vasculature in hypertensive patients. 
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